Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 8/20 | 0.47 |
| ▸ | MMP13 | P45452 | 6/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | MMP10 | P09238 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093967 | 0.92 | MMP13 (0.47) | MMP13KCNE1CCR1KCNQ1MMP10 | |
| SCHEMBL6094348 | 0.89 | MMP13 (0.44) | SOS1MMP13KCNE1CCR1KCNQ1 | |
| SCHEMBL6095011 | 0.89 | MMP13 (0.44) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6094909 | 0.88 | MMP13 (0.44) | MMP13KCNE1CCR1KCNQ1MMP10 | |
| SCHEMBL6094821 | 0.88 | KCNE1 (0.50) | SOS1KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6094065 | 0.88 | MMP13 (0.45) | MMP13KCNE1CCR1KCNQ1MMP10 | |
| SCHEMBL6094922 | 0.88 | MMP13 (0.43) | MMP13KCNE1CCR1KCNQ1 | |
| SCHEMBL6095046 | 0.88 | MMP13 (0.43) | MMP13KCNE1CCR1KCNQ1MMP10 | |
| SCHEMBL6087374 | 0.88 | MMP13 (0.43) | MMP13KCNE1CCR1KCNQ1MMP10 | |
| SCHEMBL6093299 | 0.87 | MMP13 (0.42) | MMP13KCNE1CCR1KCNQ1MMP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-7135467-B2 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | SOS1 2181/4885MMP13 4367/4885KCNE1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.